enGene Therapeutics Warrants
ENGNW
14 hedge funds and large institutions have $9.2M invested in enGene Therapeutics Warrants in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
41% more capital invested
Capital invested by funds: $6.54M → $9.2M (+$2.67M)
0.72% more ownership
Funds ownership: 11.12% → 11.84% (+0.72%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
13% less funds holding
Funds holding: 16 → 14 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$543K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$33.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIS
1
FCPM III Services
Naarden,
Netherlands
| $6.04M | – | – | – |
|
|
BI
2
BVF Inc
San Francisco,
California
| $804K | – | – | – |
|
|
BOCH
3
Blue Owl Capital Holdings
New York
| $728K | +$543K | +460,000 | +899% |
|
|
OFM
4
Omega Fund Management
Boston,
Massachusetts
| $675K | – | – | – |
|
|
SCM
5
Saba Capital Management
New York
| $274K | – | – | – |
|
6
Calamos Advisors
Naperville,
Illinois
| $214K | – | – | – |
|
7
D.E. Shaw & Co
New York
| $209K | – | – | – |
|
|
TCM
8
Tenor Capital Management
New York
| $116K | – | – | – |
|
|
WA
9
Whitebox Advisors
Minneapolis,
Minnesota
| $70K | – | – | – |
|
10
State of Wisconsin Investment Board
Madison,
Wisconsin
| $33.6K | – | – | – |
|
|
CL
11
CSS LLC
Chicago,
Illinois
| $32.9K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $2.76K | -$10.6K | -8,952 | -74% |
|
|
CS
13
Clear Street
New York
| $420 | – | – | – |
|
14
Bank of America
Charlotte,
North Carolina
| $172 | – | – | – |
|
|
WAM
15
Wolverine Asset Management
Chicago,
Illinois
| – | -$33.6K | -28,197 | Closed |
|
ENGNW Hedge Fund Activity: Q3 2024 in Review
14 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q3 2024, worth a combined $9.2M — up 41% from $6.54M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ENGNW and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Blue Owl Capital Holdings, adding an estimated $543K. The largest seller was Wolverine Asset Management, exiting entirely with an estimated $33.6K sold.
- 14 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q3 2024, down from 16 in Q2 2024.
- Funds reported $9.2M of enGene Therapeutics Warrants stock for Q3 2024, up 41% quarter-over-quarter.
- 0 funds opened new enGene Therapeutics Warrants positions in Q3 2024 and 2 closed out, a net change of -2 holders.
- The largest enGene Therapeutics Warrants buyer in Q3 2024 was Blue Owl Capital Holdings, an estimated $543K added.
- The largest enGene Therapeutics Warrants seller in Q3 2024 was Wolverine Asset Management, an estimated $33.6K sold.
Based on aggregated 13F filings for Q3 2024.